Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
PHVS Stock Chart & Stats
$29.36
-$0.46(-2.39%)
At close: 4:00 PM EST
$29.36
-$0.46(-2.39%)
Day’s Range― - ―
52-Week Range$11.51 - $29.67
Previous CloseN/A
Volume14.65K
Average Volume (3M)280.21K
Market Cap
$1.55B
Enterprise Value$1.17B
Total Cash (Recent Filing)$329.29M
Total Debt (Recent Filing)$578.66K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Apr 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding64,055,640
10 Day Avg. Volume383,119
30 Day Avg. Volume280,215
Financial Highlights & Ratios
PEG Ratio1.31
Price to Book (P/B)3.73
Price to Sales (P/S)0.00
P/FCF Ratio-8.29
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.03K
Enterprise Value/Ebitda-7.52
Forecast
1Y Price Target
$41.00Price Target Upside39.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPharvaris announced positive results for the Ph3 RAPIDe-3 trial, with the study meeting its primary and all secondary endpoints with statistical significance.
Financial StabilityPharvaris has a strong cash position with €329mn in cash and cash equivalents, providing a runway well into 1H27.
Market PotentialThe HAE market is considered large enough for multiple players, and Pharvaris' strong data supports its potential to capture market share.
Bears Say
Physician PreferenceDeucri’s opportunity in on-demand HAE would be dependent on its ability to become preferred among physicians.
Response Bias ConcernsThere could be some responder and expectancy bias driving the open-label results due to rapid, reliable benefit causing some responder oversampling.
Pharvaris News
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $11.51 and its highest was $29.66 in the past 12 months.
What is Pharvaris’s market cap?
Pharvaris’s market cap is $1.55B.
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Apr 14, 2026 which is in 129 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Nov 12, 2025. The company reported -$0.695 earnings per share for the quarter, beating the consensus estimate of -$0.748 by $0.053.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharvaris have?
Pharvaris has 64,055,640 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -$0.695 in its last earnings report, beating expectations of -$0.748. Following the earnings report the stock price went up 7.007%.
Which hedge fund is a major shareholder of Pharvaris?
Currently, no hedge funds are holding shares in PHVS
Pharvaris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (39.65% Upside)
$41.00 (39.65% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 900.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 20.0%
Last 30 Days ▲ 20.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.45%
12-Months-Change
Fundamentals
Return on Equity
-51.81%
Trailing 12-Months
Asset Growth
13.93%
Trailing 12-Months
Company Description
Pharvaris
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
PHVS Stock 12 Month Forecast
Average Price Target
$41.00
▲(39.65% Upside)
Technical Analysis
Ownership Overview
―
Insiders
8.26% Mutual Funds
71.28% Other Institutional Investors
19.81% Public Companies and
Individual Investors